The use of star polymer nanoparticles for the delivery of siRNA to mouse orthotopic pancreatic tumor models

7Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Pancreatic cancer is a lethal malignancy which is refractory to most chemotherapy drugs. Recent landmark studies have shed new light on the complex genetic heterogeneity of pancreatic cancer and provide an opportunity to utilize “precision-based medicines” to target genes based on the genetic profile of an individual’s tumor to increase the efficiency of chemotherapy and decrease tumor growth and metastases. Gene-silencing drugs in the form of short-interfering RNA (siRNA) have the potential to play an important role in precision medicine for pancreatic cancer by silencing the expression of genes including those considered difficult to inhibit (undruggable) using chemical agents. However, before siRNA can reach its clinical potential a delivery vehicle is needed to carry siRNA across the cell membrane and into the cytoplasm of the cell. Herein, we detail the methods required to use star polymer nanoparticles to deliver siRNA to pancreatic tumors in an orthotopic pancreatic cancer mouse model to silence the expression of an “undruggable” gene (βIII-tubulin) that regulates pancreatic cancer growth and chemosensitivity.

Cite

CITATION STYLE

APA

McCarroll, J. A., Sharbeen, G., Kavallaris, M., & Phillips, P. A. (2019). The use of star polymer nanoparticles for the delivery of siRNA to mouse orthotopic pancreatic tumor models. In Methods in Molecular Biology (Vol. 1974, pp. 329–353). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9220-1_23

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free